Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AK3280 Cream
- Development stage
- Phase 2
- Lead developer
- Ark Biosciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
AK3280 Cream (also known as AK3287) is an innovative topical cream formulation designed specifically for the treatment of hypertrophic scars. It is derived from AK3280, which is a next-generation broad-spectrum anti-fibrotic molecule optimized from the marketed drug pirfenidone. The cream formulation works by reducing cell proliferation and inhibiting the synthesis and accumulation of extracellular matrix, thereby exerting its therapeutic effect on fibrotic conditions of the skin.
02
Targets
LPAR1 (Lysophosphatidic acid receptor 1)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on AK3280 Cream.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AK3280 Cream.